Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT04956640
Trial Phases:	Phase I Phase II	Protocol IDs:	LOXO-RAS-20001 (primary) NCI-2021-09724 2021-000595-12 2022-502756-31-00 J3M-OX-JZQA KEYNOTE E27 MK-3475-E27/KEYNOTE E27
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	Eli Lilly and Company
NCI Full Details:	http://clinicaltrials.gov/show/NCT04956640

Summary

The purpose of this study is to find out whether the study drug, LY3537982, is safe and
effective in cancer patients who have a specific genetic mutation (KRAS G12C). Patients
must have already received or were not able to tolerate the standard of care, except for
specific groups who have not had cancer treatment. The study will last up to
approximately 4 years.

Objectives

This is an open-label, multicenter Phase 1/2 study to evaluate safety, tolerability, and
preliminary efficacy of oral LY3537982 in patients with KRAS G12C-mutant solid tumors.

This study will be conducted in 4 parts: Phase 1a dose escalation, Phase 1b dose
expansion, Phase 1b dose optimization, and Phase 2. KRAS G12C mutations will be
identified through standard of care testing.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.